Multi-target drug candidates for the treatment of triple-negative breast cancer
Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
1. A method of treating cancer in a patient, the method comprising:
administering a multi-functional agent to a patient in need thereof;
wherein the multi-functional agent has the formula I:
wherein:
R 1 is a C 1 -C 6 alkyl group, a C 2 -C 6 alkenyl group, an aryl group, a heteroaryl group, a C 3 -C 8 cycloalkyl group, or a C 3 -C 8 cycloalkenyl group;
R 2 is H, a C 1 -C 6 alkyl group, a C 2 -C 6 alkenyl group, an aryl group, a heteroaryl group, a C 3 -C 8 cycloalkyl group, or a C 3 -C 8 cycloalkenyl group; and
R 3 is a C 1 -C 6 alkyl group, a C 2 -C 6 alkenyl group, an aryl group, a heteroaryl group, a C 3 -C 8 cycloalkyl group, or a C 3 -C 8 cycloalkenyl group;
wherein the cancer is triple-negative breast cancer.
2. The method of claim 1 , wherein:
R 1 is a C 1 -C 6 alkyl group;
R 2 is H; and
R 3 is an aryl group.
3. The method of claim 1 , wherein the multi-functional agent has the formula: